MiNK Therapeutics Reports Third Quarter 2026 Financial Results

MiNK Therapeutics reported a third-quarter 2026 net loss of $2.6 million, or $0.50 per share, a 23% reduction in loss per share from the prior-year quarter. The company recorded $0.2 million in pre-commercial revenue from agenT-797 supplied through a named-patient access program and ended the quarter with $7.5 million in cash and cash equivalents. Its Phase 2 agenT-797 study for acute lung injury and respiratory failure is enrolling patients in Ukraine; U.S. dosing is anticipated by year-end 2026, with data expected in the second half of 2027.